Transient protection of normal cells during chemotherapy
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
1. A method of treating a human with cancer comprising:
administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:
or a pharmaceutically acceptable salt thereof; and,
administering to the human a chemotherapeutic agent;
wherein the selective CDK4/6 inhibitor is administered to the human about 24 hours or less prior to administration of the chemotherapeutic agent.
2. The method of claim 1 , wherein the selective CDK4/6 inhibitor is administered to the human about 4 hours or less prior to administration of the chemotherapeutic agent.
3. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of etoposide, carboplatin, gemcitabine, topotecan, paclitaxel, docetaxel, doxorubicin, cisplatin, and fluorouracil, and a combination thereof.
4. The method of claim 1 , wherein the cancer is lung cancer.
5. The method of claim 1 , wherein the cancer is breast cancer.
6. The method of claim 1 , wherein the cancer is human papilloma virus positive head and neck cancer.
7. The method of claim 1 , wherein the cancer is cervical cancer.
8. The method of claim 1 , wherein the cancer is prostate cancer.
9. The method of claim 1 , wherein the cancer is bladder cancer.
10. The method of claim 1 , wherein the cancer is colorectal cancer.
11. The method of claim 4 , wherein the lung cancer is small cell lung cancer.
12. The method of claim 5 , wherein the breast cancer is triple negative breast cancer.
13. The method of claim 3 , wherein the chemotherapeutic agent is etoposide.
14. The method of claim 3 , wherein the chemotherapeutic agent is carboplatin.
15. The method of claim 3 , wherein the chemotherapeutic agent is gemcitabine.
16. The method of claim 3 , wherein the chemotherapeutic agent is topotecan.
17. The method of claim 3 , wherein the chemotherapeutic agent is paclitaxel.
18. The method of claim 3 , wherein the chemotherapeutic agent is docetaxel.
19. A method of treating a human with triple negative breast cancer comprising:
administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:
or a pharmaceutically acceptable salt thereof; and,
administering to the human a chemotherapeutic agent;
wherein the selective CDK4/6 inhibitor is administered to the human 24 hours or less prior to administration of the chemotherapeutic agent.
20. The method of claim 19 , wherein the selective CDK4/6 inhibitor is administered to the human 4 hours or less prior to administration of the chemotherapeutic agent.
21. The method of claim 19 , wherein the selective CDK4/6 inhibitor is administered to the human ½ hour or less prior to administration of the chemotherapeutic agent.
22. The method of claim 19 , wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, gemcitabine, paclitaxel, doxorubicin, cyclophosphamide, and a combination thereof.
23. The method of claim 22 , wherein the chemotherapeutic agent is carboplatin.
24. The method of claim 22 , wherein the chemotherapeutic agent is gemcitabine.
25. The method of claim 22 , wherein the chemotherapeutic agent is paclitaxel.
26. The method of claim 22 , wherein the chemotherapeutic agent is doxorubicin.
27. The method of claim 1 , wherein the selective CDK4/6 inhibitor is administered to the human ½ hour or less prior to administration of the chemotherapeutic agent.
28. The method of claim 3 , wherein the chemotherapeutic agent is cisplatin.
29. The method of claim 3 , wherein the chemotherapeutic agent is 5-fluorouracil.
30. The method of claim 22 , wherein the chemotherapeutic agent is cyclophosphamide.